Patents by Inventor Anita Difrancesco

Anita Difrancesco has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING FIBROSIS
    Publication number: 20230201195
    Abstract: The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-CoV-2. Lung function stabilizes or is improved as a result of treatment.
    Type: Application
    Filed: February 28, 2023
    Publication date: June 29, 2023
    Inventors: Miguel de los Rios, John Hood, Anita Difrancesco
  • METHODS OF TREATING FIBROSIS
    Publication number: 20230201196
    Abstract: The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-CoV-2. Lung function stabilizes or is improved as a result of treatment.
    Type: Application
    Filed: February 28, 2023
    Publication date: June 29, 2023
    Inventors: Miguel de los Rios, John Hood, Anita Difrancesco, Luis A. Dellamary, Sunil K. KC
  • Method of treating fibrosis
    Patent number: 11628167
    Abstract: The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-CoV-2. Lung function stabilizes or is improved as a result of treatment.
    Type: Grant
    Filed: May 3, 2022
    Date of Patent: April 18, 2023
    Assignee: Endeavor Biomedicines, Inc.
    Inventors: Miguel de los Rios, John Hood, Anita Difrancesco
  • METHOD OF TREATING FIBROSIS
    Publication number: 20220265650
    Abstract: The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-CoV-2. Lung function stabilizes or is improved as a result of treatment.
    Type: Application
    Filed: May 3, 2022
    Publication date: August 25, 2022
    Inventors: Miguel de los Rios, John Hood, Anita Difrancesco